STAT3-IN-19
STAT3-IN-19 is an orally active and selective STAT3 inhibitor. STAT3-IN-19 inhibits STAT3 Tyr705 phosphorylation, downregulates the expression of downstream Cyclin D1, Bcl‑xL, and survivin target genes, inhibits colorectal cancer cell proliferation, migration, and sphere formation, and induces apoptosis. STAT3-IN-19 exhibits antitumor efficacy in colorectal cancer xenograft models and synergizes with Capecitabine (HY-B0016) to inhibit colorectal tumor growth. STAT3-IN-19 can be used for research on colorectal cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C17H13N3O3S
- 분자량:339.37
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
STAT3 4.91 μM (Kd) |
STAT3 4.67 μM (Kd) |
Cdk4/cyclin D1 |
Bcl-xL |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.64 μM
|
Antiproliferative activity against human HCT-116 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human HCT-116 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| SW-620 | IC50 |
0.71 μM
|
Antiproliferative activity against human SW620 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human SW620 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| HT-29 | IC50 |
0.83 μM
|
Antiproliferative activity against human HT29 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human HT29 colorectal cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| HL-60 | IC50 |
1.71 μM
|
Antiproliferative activity against human HL-60 cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human HL-60 cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| THP-1 | IC50 |
1.11 μM
|
Antiproliferative activity against human THP-1 cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human THP-1 cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| BXPC-3 | IC50 |
9.86 μM
|
Antiproliferative activity against human BxPC-3 pancreatic cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human BxPC-3 pancreatic cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| PANC-1 | IC50 |
4.10 μM
|
Antiproliferative activity against human PANC1 pancreatic cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against human PANC1 pancreatic cancer cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
| NCM460 | IC50 |
3.02 μM
|
Antiproliferative activity against normal human NCM460 colon mucosal epithelial cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
Antiproliferative activity against normal human NCM460 colon mucosal epithelial cells assessed as viability reduction incubated 24 hrs by CCK-8 assay.
|
acs.jmedchem.6c01573 |
In Vitro
STAT3-IN-19 shows increased IC50 in STAT3-knockdown HCT-116 and HT29 cells, indicating that its antiproliferative activity depends on STAT3[1].
STAT3-IN-19 (0.5-2 μM; 0-48 h) selectively decreases STAT3 Tyr705 phosphorylation in HCT-116 and HT29 cells without significantly altering total STAT3 levels[1].
STAT3-IN-19 (0.5-2 μM; 24 h) promotes PARP cleavage in HCT-116 and HT29 cells[1].
STAT3-IN-19 (0.5-2 μM; 14 days) inhibits clonogenic growth of HCT-116 and HT29 cells[1].
STAT3-IN-19 (0.5-1 μM; 24 h) inhibits HCT-116 migration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT-116 and HT29 cells
-
Concentration:0.5, 1, 1.5, 2 μM (24 h)
2 μM (0-48 h) -
Incubation Time:24 h
0, 3, 6, 12, 24, 48 h -
Result:Inhibited STAT3 Tyr705 phosphorylation in a dose-dependent manner from 0.5 to 2 μM with minimal effect on total STAT3.
In HCT-116 cells, pSTAT3 began to decline at 6 h and was almost diminished at 24-48 h.
In HT29 cells, sustained inhibition of STAT3 phosphorylation was observed 24 h after exposure.
-
Cell Line:HCT-116 and HT29 cells
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:14 days
-
Result:Suppressed clonogenic growth of HCT-116 and HT29 cells, with near-complete inhibition at 2 μM.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 1 μM
-
Incubation Time:24 h
-
Result:Prevented HCT-116 migration at 0.5 and 1 μM.
-
Cell Line:HCT-116 and HT29 cells
-
Concentration:1, 2 μM
-
Incubation Time:24 h
-
Result:Decreased BCL2L1, Cyclin D1, and Survivin mRNA levels in a concentration-dependent manner in both HCT-116 and HT29 cells.
-
Cell Line:HCT-116 and HT29 cells
-
Concentration:0.5, 1, 1.5, 2 μM
-
Incubation Time:24 h
-
Result:Reduced Cyclin D1, Bcl-xL, and Survivin protein levels in HCT-116 and HT29 cells.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in HCT-116 cells in a dose-dependent manner, with the largest apoptotic fraction at 2 μM.
In Vivo
STAT3-IN-19 (150 mg/kg; i.g.; once daily; for 21 consecutive days) potently inhibits HCT-116 xenograft tumor growth in BALB/c nude mice, with a TGI of 86%[1].
STAT3-IN-19 (50 mg/kg; i.g.; 21 consecutive days) inhibits HCT-116 xenograft tumor growth in BALB/c nude mice, and its combination with Capecitabine (HY-B0016) (100 mg/kg) achieves 84% TGI[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-nude (female, 5 weeks old, 8 × 106 HCT-116 cells dispersed in 100 μL normal saline (pH 7.0))[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.v.; once daily; 14 consecutive days
-
Result:Inhibited tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) of 68% at 10 mg/kg and 81% at 20 mg/kg.
-
Animal Model:BALB/c-nude (female, 5 weeks old, 8 × 106 HCT-116 cells dispersed in 100 μL normal saline (pH 7.0))[1]
-
Dosage:150 mg/kg
-
Administration:i.g.; once daily; 21 consecutive days
-
Result:Inhibited HCT-116 xenograft tumor growth in BALB/c nude mice, with a TGI of 86%.
- RNA extraction experimental
- Cell migration
- Somatic Cell Culture
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Apoptosis Solutions
- MTT Cell Proliferation Assay
- Western Blot
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- Patient-Derived Orthotopic Xenograft (PDOX)
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- Kinase activity and phosphorylation assays
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Patient-Derived Xenograft (PDX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Protocol for Kinase activity and phosphorylation assays
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Parmacokinetics
Chemical Information
-
분자량 339.37
-
화학식 C17H13N3O3S
-
SMILES
O=C1C(C2=CC(N)=CC=C2)=C(NC)C3=NS(C4=C3C1=CC=C4)(=O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)